Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells

Leukemia and Lymphoma

Volumn 50, Issue 4, 2009, Pages 625-632

  Hayun, Rami ^a   Okun, Eitan ^a   Berrebi, Alain ^b   Shvidel, Lev ^b   Bassous, Lucette ^b   Sredni, Benjamin ^a   Nir, Uri ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

Author keywords

B chronic lymphocytic leukemia (B CLL); Caspase; Curcumin; Rapamycin; Sirolimus; Turmeric

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 9; CD19 ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; CURCUMIN; LIPOCORTIN 5; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2; RAPAMYCIN;

ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; BLOOD SAMPLING; CELL ISOLATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKOCYTE COUNT; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CASPASE 3; CASPASE 7; CASPASE 9; CURCUMIN; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; SIROLIMUS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 68449098158     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902789181     Document Type: Article

References (17)

1. Brugiatelli M, Bandini G, Barosi G, Lauria F, Liso V, Marchetti M, et al. Management of chronic lymphocytic leukemia: Practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2006;91:1662-1673.
2. Chiorazzi N, Ferrarini M. Evolving view of the in vivo kinetics of chronic lymphocytic leukemia B cells. Hematology Am Soc Hematol Educ Program 2006;512:273-278.
3. Everett PC, Meyers JA, Makkinje A, Rabbi M, Lerner A. Preclinical assessment of curcumin as a potential therapy for B-CLL. Am J Hematol 2007;82:23-30.
4. Jagetia GC, Aggarwal BB. "Spicing up" of the immune system by curcumin. J Clin Immunol 2007;27:19-35.
5. Ramalingam S, Belani CP. Recent advances in targeted therapy for non-small cell lung cancer. Expert Opin Ther Targets 2007;11:245-257.
6. Singh S, Khar A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med Chem 2006;6:259-270.
7. Swat W, Ignatowicz L, Kisielow P. Detection of apoptosis of immature CD4+8+thymocytes by flow cytometry. J Immunol Methods 1991;137:79-87.
8. Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F, et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003;101:278-285.
9. Faried LS, Faried A, Kanuma T, Nakazato T, Tamura T, Kuwano H, et al. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel. Eur J Cancer 2006;42:934-947.
10. Bokelmann I, Mahlknecht U. Valproic acid sensitises chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins. Mol Med 2008;14:20-27.
11. Garcia JA, Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 2008;7:1347-1354.
12. Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008;19:1387-1392.
13. Decker T, Sandherr M, Goetze K, Oelsner M, Ringshausen I, Peschel C. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced BCLL. Ann Hematol 2009;88:221-227.
14. Binion DG, Otterson MF, Rafiee P. Curcumin inhibits VEGF mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK Inhibition. Gut 2008;57:1509-1517.
15. Sun CY, Liu XY, Chen Y, Liu F, Wang Y. Experimental study on anticancer effect of curcumin on Raji cells in vitro. Zhongguo Zhong Xi Yi Jie He Za Zhi 2004;24:1003-1006.
16. Gotze KS, Hoffmann D, Schatzl HM, Peschel C, Fend F, Decker T. Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells. Haematologica 2007;92:1282-1283.
17. Ringshausen I, Peschel C, Decker T. Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: A new therapeutic option. Leuk Lymphoma 2005;46:11-19.